Abstract 1873P
Background
Patients living with myeloproliferative neoplasms (MPN), including myelofibrosis (MF), polycythaemia vera (PV) and essential thrombocythemia (ET), should engage in self-care behaviours to improve their health. This study aims to preliminary assess self-care behaviours in MPN patients.
Methods
A descriptive cross-sectional study has been conducted in 9 haematology centres in Italy since November 2021. The Italian Association of MPN Patients (AIPAMM) promoted this study. The Self-Care in MyeloProliferative Neoplasms Inventory (SC-MPNI), a 31-item questionnaire measuring self-care behaviours according to the Middle-Range Theory of Self-Care of Chronic Illness, was developed and tested for its content validity. MPN patients were asked to complete a paper-and-pencil questionnaire during their outpatient visit or at home.
Results
Preliminary data from 171 patients (54% male; mean age=58, SD=19) and 5 centres were analysed (45.6% of the expected sample). Participants were living with overt MF (n=51), prefibrotic MF (n=24), PV (n=48) or ET (n=44). Concerning self-care maintenance, the most frequent behaviour was attending all scheduled clinical appointments (M=5.9, SD=0.6), and the least used one was performing activities that improve mental and physical well-being (M=3.1, SD=1.7). Concerning self-care monitoring, the most frequent behaviour was getting blood tests as prescribed by the haematologist (M=5.9, SD=0.5), and the least used one was checking any measurement the healthcare providers recommend (M=4.7, SD=1.4). Concerning self-care management, the most frequent behaviour was accurately reporting symptoms to the healthcare providers during visits to get a comprehensive response (M=5.5, SD=0.9), and the least used one was asking for psychological support to overcome emotional problems (M=2.6, SD=1.5).
Conclusions
This study will contribute to assessing self-care behaviours in patients with MPN. Health professionals should support innovative interventions to promote self-care, which is crucial for MPN patients to reduce cardiovascular events and be medically fit to undergo hematopoietic stem cell transplantation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05